A Feasibility Study of the Therapeutic Response and Durability of Short-term Androgen-targeted Therapy in Early Prostate Cancer Managed with Surveillance: The Therapeutics in Active Prostate Surveillance (TAPS01) Study
Publication: European Urology Open Science
Tristan Barrettab, Simon Paceyacde, Kelly Leonard, Jerome Wulff, Ionut-Gabriel Funinganacd, Vincent Gnanapragasam
10 February 2022
Summary
Active surveillance (AS) is a preferred management option for men with prostate cancer with favourable prognosis. However, nearly half of men on AS switch to treatment within 5 years, so therapeutic strategies to prevent or delay disease progression could be considered.
Researchers explored image-based tumour responses and the patient impact of short-duration androgen-targeted therapy to abrogate disease progression during AS.
